FDA De Novo Classification Strategy

FDA reviewers provided constructive comments regarding the proposed indications for use, recommended refinements to the clinical evaluation strategy, emphasized expectations for software documentation, and discussed appropriate approaches for validating algorithm performance across representative patient populations.

Receiving this feedback early allowed the client to optimize development activities before committing significant additional resources.

Addressing Artificial Intelligence Considerations

Artificial intelligence introduces unique regulatory considerations beyond those encountered in traditional software.

eeMeds™ worked closely with software engineers and data scientists to establish documentation supporting transparency, repeatability, and performance consistency.

Algorithm development processes were documented from initial concept through model selection, training, testing, validation, and deployment.

Special attention was given to:

· Data quality

· Dataset representativeness

· Bias evaluation

· Performance consistency

· False positive and false negative analysis